Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers

This study is testing whether taking two tablets of F/TAF (a combination HIV prevention medication also called Descovy) in a single dose provides effective drug levels for preventing HIV. This explores a simplified dosing approach that could be relevant for on-demand HIV pre-exposure prophylaxis (PrEP). **You may be eligible if...** - You are 18 or older and currently HIV-negative - You are in generally good health - Your kidneys are functioning well (eGFR of 70 or higher) - You agree to use condoms during the study and to not take other PrEP medications outside the study **You may NOT be eligible if...** - You have used F/TDF or F/TAF (oral PrEP) in the past 2 months - You test positive for HIV or hepatitis B - You have had gastrointestinal surgery that could affect how the drug is absorbed - You are pregnant or breastfeeding - You are taking medications known to affect drug absorption Talk to your doctor to see if this trial is right for you.